{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Ovarian+Carcinoma&page=5", "query": { "condition": "Advanced Ovarian Carcinoma", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 697, "total_pages": 70, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Ovarian+Carcinoma&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Ovarian+Carcinoma&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T06:02:56.927Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04803305", "title": "Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Pancreatic Cancer", "Colorectal Cancer", "Prostate Cancer", "Breast Cancer", "Ovarian Cancer", "Loss of Appetite", "Fatigue", "Cachexia", "Anorexia" ], "interventions": [ { "name": "PF-06946860", "type": "DRUG" }, { "name": "Placebo for PF-06946860", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2021-05-11", "completion_date": "2022-08-09", "has_results": true, "last_update_posted_date": "2024-01-12", "last_synced_at": "2026-10-03T06:02:56.927Z", "location_count": 32, "location_summary": "Little Rock, Arkansas • Beverly Hills, California • Camarillo, California + 21 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Camarillo", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04803305" }, { "nct_id": "NCT04503265", "title": "A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Malignant Neoplasm", "Breast Cancer", "Ovarian Cancer", "Homologous Recombination Deficiency", "Prostate Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "AMXI-5001:Dose Escalation Phase I", "type": "DRUG" }, { "name": "AMXI-5001:Dose Expansion Phase II", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AtlasMedx, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2020-08-12", "completion_date": "2026-10", "has_results": false, "last_update_posted_date": "2025-05-01", "last_synced_at": "2026-10-03T06:02:56.927Z", "location_count": 4, "location_summary": "Los Angeles, California • Baltimore, Maryland • Nashville, Tennessee + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04503265" }, { "nct_id": "NCT06690775", "title": "CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Epithelial Ovarian Cancer", "Primary Peritoneal", "Fallopian Tube Cancer", "Endometrioid Ovarian Cancer" ], "interventions": [ { "name": "TORL-1-23", "type": "DRUG" }, { "name": "Pegfilgrastim (drug)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TORL Biotherapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 230, "start_date": "2024-11-20", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-10-03T06:02:56.927Z", "location_count": 26, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Duarte, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06690775" }, { "nct_id": "NCT00002901", "title": "Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Head and Neck Cancer", "Lung Cancer", "Ovarian Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1996-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-01-13", "last_synced_at": "2026-10-03T06:02:56.927Z", "location_count": 3, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002901" }, { "nct_id": "NCT02222922", "title": "A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "PF-06647020 Q3W", "type": "DRUG" }, { "name": "fluconazole", "type": "DRUG" }, { "name": "PF-06647020 Q2W", "type": "DRUG" }, { "name": "PF-06647020 combined with Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2014-10-17", "completion_date": "2019-11-05", "has_results": true, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-10-03T06:02:56.927Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02222922" }, { "nct_id": "NCT00090727", "title": "Chemotherapy for Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Malignancies", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "AQ4N", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novacea", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2004-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2006-11-02", "last_synced_at": "2026-10-03T06:02:56.927Z", "location_count": 2, "location_summary": "The Bronx, New York • San Antonio, Texas", "locations": [ { "city": "The Bronx", "state": "New York" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00090727" }, { "nct_id": "NCT02837991", "title": "A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma (RCC)", "Clear-cell Renal Cell Carcinoma", "Papillary Renal Cell Carcinoma", "Kidney Neoplasms", "Metastatic Renal Cell Carcinoma", "Ovarian Clear Cell Carcinoma" ], "interventions": [ { "name": "CDX-014", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2016-06", "completion_date": "2018-11-16", "has_results": false, "last_update_posted_date": "2020-06-04", "last_synced_at": "2026-10-03T06:02:56.927Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Boston, Massachusetts + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Buffalo", "state": "New York" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02837991" }, { "nct_id": "NCT05059522", "title": "Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Malignancies", "NSCLC", "Ovarian Cancer", "Urothelial Cancer", "Solid Tumors" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Lorlatanib", "type": "DRUG" }, { "name": "Talazoparib", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Axitinib", "type": "DRUG" }, { "name": "CMP 001", "type": "DRUG" }, { "name": "Utomilumab", "type": "DRUG" }, { "name": "PF04518600", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2021-09-29", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-03T06:02:56.927Z", "location_count": 20, "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05059522" }, { "nct_id": "NCT00377429", "title": "Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer" ], "interventions": [ { "name": "catumaxomab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neovii Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 47, "start_date": "2006-09", "completion_date": "2008-02", "has_results": true, "last_update_posted_date": "2012-07-19", "last_synced_at": "2026-10-03T06:02:56.927Z", "location_count": 12, "location_summary": "Tucson, Arizona • Stanford, California • Orlando, Florida + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Hinsdale", "state": "Illinois" }, { "city": "South Bend", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00377429" }, { "nct_id": "NCT02159989", "title": "Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Fibrolamellar Carcinoma", "Metastatic Malignant Solid Neoplasm", "Ovarian Carcinoma", "Pancreatic Neuroendocrine Tumor", "Recurrent Malignant Solid Neoplasm", "Refractory Malignant Solid Neoplasm", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Ziv-Aflibercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2014-06-18", "completion_date": "2024-01-29", "has_results": true, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-10-03T06:02:56.927Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02159989" } ] }